dopamine antagonism, noradrenaline antagonism, subjective probability processing, subjective value processing, dopamine antagonisme, noradrenaline antagonisme, subjectieve waardevolheid, subjectieve waarschijnlijkheid.
Conditions
Interventions
- one capsule containing 150 microgram clonidine
- one capsule containing 2 milligram haloperidol
- one capsule containing placebo
Sponsors
Utrecht University
Eligibility
Inclusion criteria
Inclusion criteria: Male, non-smoking, age between 18-45 years and passing the screening (assessing medical history and blood pressure/heart rate)
Exclusion criteria
Exclusion criteria: Psychopathology, current medication use, (history of) serious medical condition(s), low blood pressure, heart rate above 100 bpm or below 60 bpm in rest.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cue specific P200 event-related potential relative to no cue, cue specific P300 event-related potential relative to no cue. Independent variables: Subjective value, Subjective probability, dopaminergic antagonism by haloperidol and noradrenergic antagonism by clonidine. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Velocity scaling measurement - Spontaneous motor activity measurement - Event related potentials in response to the target - Reaction times in response to the target - Target omissions and percentage correct responses - Questionnaire scores (attentional control, State-trait anxiety inventory) | — |
Contacts
Public ContactIris Schutte
Utrecht University, experimental psychology dept.
Outcome results
None listed